SNA HPV therapeutic vaccine

The SNA HPV therapeutic vaccine is a spherical nucleic acid (SNA)-based nanovaccine developed by Flashpoint Therapeutics in collaboration with Northwestern University. It is designed as a therapeutic intervention for established HPV-driven cancers, including cervical and head and neck cancers. The vaccine utilizes a structural nanomedicine approach, where a nanoscale lipid core is surrounded by a globular shell of immune-activating CpG DNA (adjuvant) and HPV16 E7-derived peptide antigens (specifically E7₁₁₋₁₉). This unique architecture ensures the co-delivery of antigen and adjuvant to the same immune cells, optimizing the activation of CD8+ 'killer' T cells to recognize and destroy tumor cells expressing the HPV E7 oncoprotein. Preclinical data published in 2026 demonstrated significant tumor growth inhibition and improved survival in humanized models.

Other names

SNA-based HPV vaccinestructural nanomedicine HPV vaccine